In August, the executive changes were counted, the founders retired, and the CEOs of many pharmaceutical companies were adjusted

Affected by the economy this year, coupled with clinical failures, business adjustments, structural restructuring and other reasons, the layoffs of foreign pharmaceutical companies have intensified, and senior executives such as CEOs are not spared

In this environment, domestic executive changes and personnel adjustments are relatively frequent, local pharmaceutical companies continue to introduce overseas executives, biotech many core executives resign, well-known pharmaceutical founders retire and so on

According to incomplete statistics from The Pharmaceutical Cube, a total of 22 executives changed positions in August this year, of which 17 executives ushered in new job appointments and 5 senior executives resigned

From the inventory of the changes in senior management in the pharmaceutical industry in August, it can be seen that talents with overseas work backgrounds are more favored

Tengsheng Bo Pharmaceutical, the first company to successfully promote the commercialization stage of domestic new crown neutralizing antibodies, recently announced a total of 3 personnel appointments, and the candidates were from abroad

Companies such as Genxi Biology, Keyue Pharmaceutical, Pufang Biologics, Chuangsheng Group, Yahong Pharmaceutical, and Boaoxin also introduced overseas executives

In addition, the more concerned personnel adjustments in China include the departure of Liu Min, chief commercial officer of Cinda Biologics, Bo Kerui, CEO of Genting Xinyao, and the retirement

Min Liu is one of the first employees of Cinda's commercialization team and is responsible for the company's business operations, including market sales and market access

Prior to joining Genting ShinYao, Bo served as Chief Scientific Officer of Cinda Biologics and Senior Vice President of External Innovation at Eli Lilly China

Jiang Ningjun is the founder of CStone Pharmaceuticals, and after leading the company's development for six years, he decided to retire